Literature DB >> 31758258

Surgical outcomes of vitrectomy surgery for proliferative diabetic retinopathy in patients with abnormal renal function.

P Larrañaga-Fragoso1, H Laviers2, C McKechnie3, H Zambarakji3.   

Abstract

PURPOSE: To analyse the influence of renal function on the outcomes of vitrectomy for tractional-related complications in cases of severe proliferative diabetic retinopathy (PDR).
METHODS: Retrospective consecutive case series of 109 eyes that underwent vitreoretinal interventions for traction-related complications of severe PDR from 2014 to 2017. Data collected included patient demographics, best-corrected visual acuity (BCVA), surgical complications, and systemic markers including HbA1c and estimated glomerular filtration rate (eGFR). Renal function categories were defined as low (eGFR < 30 mL/min/1.73 m2), medium (eGFR 30-60 mL/min/1.73 m2), and normal (eGFR > 60 mL/min/1.73m 2).
RESULTS: A total of 109 eyes (56% (n = 61) female) were included in the study. Overall, mean baseline BCVA improved from 1.33 logMAR to 0.91 logMAR (p < 0.001) postoperatively. Patients with low eGFR had significantly worse baseline BCVA (p = 0.039) and demonstrated greater improvement in mean BCVA (p = 0.059). Multivariate regression analysis indicated that seven predictors explained 65.5% of the variance (R2 = 0.655, F(11,97) = 16.7, p < 0.01).
CONCLUSIONS: Reduced renal function does not adversely affect visual outcomes of vitrectomy for traction-related complications of PDR.

Entities:  

Keywords:  Delamination; Diabetes; Diabetic retinopathy; Renal function; Tractional retinal detachment; Vitrectomy

Mesh:

Year:  2019        PMID: 31758258     DOI: 10.1007/s00417-019-04532-7

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  24 in total

1.  Vitrectomy with silicone oil infusion in severe diabetic retinopathy.

Authors:  A Castellarin; R Grigorian; N Bhagat; L Del Priore; M A Zarbin
Journal:  Br J Ophthalmol       Date:  2003-03       Impact factor: 4.638

2.  Results of vitrectomy for proliferative diabetic retinopathy.

Authors:  J T Thompson; S de Bustros; R G Michels; T A Rice; B M Glaser
Journal:  Ophthalmology       Date:  1986-12       Impact factor: 12.079

3.  Visual outcome and risk factors for light perception and no light perception vision after vitrectomy for diabetic retinopathy.

Authors:  John O Mason; Cheri T Colagross; Troy Haleman; Jeffrey J Fuller; Milton F White; Richard M Feist; Tracy L Emond; Gerald McGwin
Journal:  Am J Ophthalmol       Date:  2005-08       Impact factor: 5.258

4.  Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

Authors:  Andrew S Levey; Kai-Uwe Eckardt; Yusuke Tsukamoto; Adeera Levin; Josef Coresh; Jerome Rossert; Dick De Zeeuw; Thomas H Hostetter; Norbert Lameire; Garabed Eknoyan
Journal:  Kidney Int       Date:  2005-06       Impact factor: 10.612

Review 5.  Surgical management of the late complications of proliferative diabetic retinopathy.

Authors:  D K Newman
Journal:  Eye (Lond)       Date:  2010-02-05       Impact factor: 3.775

6.  Preoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: A Randomized and Controlled Trial Comparing Interval Variation.

Authors:  Javier Castillo; Isaac Aleman; Sloan W Rush; Ryan B Rush
Journal:  Am J Ophthalmol       Date:  2017-08-30       Impact factor: 5.258

7.  Postoperative vitreous hemorrhage after diabetic 23-gauge pars plana vitrectomy.

Authors:  Mohammed K Khuthaila; Jason Hsu; Allen Chiang; Francis Char DeCroos; Eugene A Milder; Vikram Setlur; Sunir J Garg; Marc J Spirn
Journal:  Am J Ophthalmol       Date:  2013-01-11       Impact factor: 5.258

8.  Retinopathy and chronic kidney disease in the Chronic Renal Insufficiency Cohort (CRIC) study.

Authors:  Juan E Grunwald; Judith Alexander; Gui-Shuang Ying; Maureen Maguire; Ebenezer Daniel; Revell Whittock-Martin; Candace Parker; Kathleen McWilliams; Joan C Lo; Alan Go; Raymond Townsend; Crystal A Gadegbeku; James P Lash; Jeffrey C Fink; Mahboob Rahman; Harold Feldman; John W Kusek; Dawei Xie; Bernard G Jaar
Journal:  Arch Ophthalmol       Date:  2012-09

9.  Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin).

Authors:  Wayne R Lo; Stephen J Kim; Thomas M Aaberg; Christopher Bergstrom; Sunil K Srivastava; Jiong Yan; Daniel F Martin; G Baker Hubbard
Journal:  Retina       Date:  2009 Jul-Aug       Impact factor: 4.256

10.  Chronic Kidney Disease and Diabetic Retinopathy in Patients with Type 2 Diabetes.

Authors:  Antonio Rodríguez-Poncelas; Xavier Mundet-Tudurí; Sonia Miravet-Jiménez; Aina Casellas; Joan F Barrot-De la Puente; Josep Franch-Nadal; Gabriel Coll-de Tuero
Journal:  PLoS One       Date:  2016-02-17       Impact factor: 3.240

View more
  4 in total

1.  Ocular findings, surgery details and outcomes in proliferative diabetic retinopathy patients with chronic kidney disease.

Authors:  Jipeng Li; Aman Chandra; Lin Liu; Lin Zhang; Jun Xu; Meng Zhao
Journal:  PLoS One       Date:  2022-10-21       Impact factor: 3.752

2.  Comparative Analysis of the Effects of the Anti-VEGF Drug and Glucocorticoid by Injection before the End of Vitrectomy for Proliferative Diabetic Retinopathy.

Authors:  Haijin Zhao; Xueling Li; Xiahai Zhao; Qiongfang Zhang; Wei He; Yanfei Wei; Xueshan Tang
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-21       Impact factor: 2.629

3.  Prediction of Visual Outcomes After Diabetic Vitrectomy Using Clinical Factors From Common Data Warehouse.

Authors:  Seong-Su Lee; Dong Jin Chang; Jin Woo Kwon; Ji Won Min; Kwanhoon Jo; Young-Sik Yoo; Byul Lyu; Jiwon Baek
Journal:  Transl Vis Sci Technol       Date:  2022-08-01       Impact factor: 3.048

4.  Relationship between renal function and prognosis of Chinese proliferative diabetic retinopathy patients undergoing the first vitrectomy: protocol for a prospective cohort study.

Authors:  Chunyan Lei; Keren Zhang; Tiancong Chang; Qibo Ran; Meixia Zhang
Journal:  BMJ Open       Date:  2021-12-06       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.